Condition
Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
Total Trials
4
Recruiting
0
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (1)
P 3 (1)
Trial Status
Active Not Recruiting2
Withdrawn1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03435952Phase 1Active Not Recruiting
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
NCT03028337Phase 2Active Not RecruitingPrimary
Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases
NCT02915172Phase 1Withdrawn
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
NCT00017147Phase 3CompletedPrimary
S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma
Showing all 4 trials